Zinc and Iron Absorption From Common Beans in Young Adult Women

March 22, 2024 updated by: University of California, Davis
Fifteen female study participants will be enrolled in a randomized crossover study to measure fractional and total zinc and iron absorption from four common bean (Phaseolus vulgaris) varieties with varying phytate and polyphenolic contents. Phytate, the storage form of phosphorus in plants, and polyphenols, which contribute to the varied colors of common beans, are natural components of the beans and can reduce zinc and iron bioavailability from these foods.

Study Overview

Detailed Description

Each participant will attend a total of 10 study visits. The first visit will be a screening visit to determine eligibility, and will include the administration of health history and food frequency questionnaires, and a urine pregnancy test. Participant will also be given a ASA24 24-hour dietary recall at visit 1 to return at visit 2. All subsequent visits (2 through 10) will begin with a blood sample (15 mL, or 1 tablespoon, after a 12 hour overnight fast).

Visit 2 will establish the baseline distribution of naturally occurring zinc and iron isotopes in the blood, and will include the administration of water enriched in zinc of a specific naturally-occurring isotopic mass (zinc-68, 4 mg).

Visits 2-5 will be on consecutive days, while Visit 6 will be 14 days following Visit 5. Visits 3 and 4 will include breakfast, lunch, and dinner, each containing a small serving of beans that are enriched in specific isotopic masses of iron and zinc (2 mg each of zinc-67 and iron-57, or 1 mg each of zinc-70 and iron-58). Visits 5 and 6 are for blood sampling, to measure the zinc in blood plasma (Visit 5) and the iron that has reached a 14-day equilibrium in red blood cells (Visit 6). Participants will also be given a ASA24 24-hour dietary recall at visit 6 to return at visit 7.

Visits 6-9 will be on consecutive days, starting 28 days (the approximate length of one menstrual cycle) after Visit 3, while Visit 10 will be 14 days following Visit 9. The 28-day timing is needed to minimize the potential influence of natural variation in circulating hormones, on zinc metabolism. A second urine pregnancy test will be administered on Visit 10, to detect any pregnancies that would have occurred at the time of the study meals 2 weeks prior or earlier. Participants will also be given a ASA24 dietary recall at visit 9 to return at visit 10.

Study Type

Interventional

Enrollment (Estimated)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • California
      • Davis, California, United States, 95616
        • Department of Nutrition

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy eumenorrheic (regular monthly menstrual cycles of 25-30-days in length)
  • BMI 18.5 - 30 kg/m2
  • Regular consumer of beans, i.e. ≥ 4 servings per month
  • Usual iron intake estimated by Food Frequency Questionnaire to be less than the Recommended Daily Allowance (RDA) of 18 mg/d (8)
  • Subject is willing and able to comply with the study protocols.
  • Subject is willing to participate in all study procedures.

Exclusion Criteria:

  • Dislike or allergy to beans
  • Self-reported current or recent pregnancy (within the past 12 months)
  • Self-reported recent termination of pregnancy (3 months if abortion in 1st or 2nd trimester, or 12 months if in 3rd trimester)
  • Self-reported plans to become pregnant during the study period
  • Self-reported cancer
  • Self-reported surgery without the past 12 months
  • Currently taking prescription drugs, other than for contraception, or any nutritional supplements
  • Any daily iron supplementation within the past 12 months.
  • Currently breastfeeding
  • Any medical conditions affecting iron or zinc metabolism (such as hemochromatosis or sickle cell disease)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bean Variety 1
Enriched with Zinc-67, Iron-57
Bean High in Phytic Acid and High in Inhibitory Polyphenols
Experimental: Bean Variety 2
Enriched with Zinc-70, Iron-58
Bean Low in Phytic Acid and High in Inhibitory Polyphenols
Experimental: Bean Variety 3
Enriched with Zinc-67, Iron-57
Bean Low in Phytic Acid and Low in Inhibitory Polyphenols
Experimental: Bean Variety 4
Enriched with Zinc-70, Iron-58
Bean High in Phytic Acid and Low in Inhibitory Polyphenols

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fractional Zinc absorption
Time Frame: 24 hours after first intake
amount of zinc absorbed and circulating in blood
24 hours after first intake
Fractional Iron absorption
Time Frame: 24 hours after first intake
amount of iron absorbed and circulating in the blood
24 hours after first intake

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total Zinc absorption
Time Frame: 24 hours after first intake
total amount of zinc absorbed from meals
24 hours after first intake
Total Iron absorption
Time Frame: 24 hours after first intake
total amount of iron absorbed from meals
24 hours after first intake

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrew G Hall, PhD, University of California, Davis

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2024

Primary Completion (Estimated)

August 31, 2024

Study Completion (Estimated)

December 31, 2024

Study Registration Dates

First Submitted

March 18, 2024

First Submitted That Met QC Criteria

March 18, 2024

First Posted (Actual)

March 25, 2024

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 22, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2101814

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron Absorption

Clinical Trials on SER 118

3
Subscribe